New York, USA, April 05, 2023 (GLOBE NEWSWIRE) -- Basal Cell Carcinoma Market to Grow at a Substantial Growth Rate | MEDIVIR, Biofrontera Bioscience, Mediwound, AiViva's, Sirnaomics, Pellepharm, Senhwa Biosciences, Inc., Palvella Therapeutics, Inc., and Others Expected to Propel Market
The basal cell carcinoma market is anticipated to show immense growth in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2023–2032.
DelveInsight’s Basal Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, basal cell carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Basal Cell Carcinoma Market Report
- As per DelveInsight analysis, the basal cell carcinoma market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- As per American Society of Dermatology Association (2022) estimates that nonmelanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), affects more than 3 million Americans a year.
- Leading basal cell carcinoma companies such as Medivir, Sirnaomics, AiViva BioPharma, Inc., Ascend Biopharmaceuticals Ltd, Lytix Biopharma, Senhwa Biosciences, Inc., Palvella Therapeutics, Inc., Genzada Pharmaceuticals USA, Inc., Philogen S.p.A., Incyte Corporation, and others are developing novel basal cell carcinoma drugs that can be available in the basal cell carcinoma market in the coming years.
- Some of the key therapies for basal cell carcinoma treatment include Remetinostat, STP705, AIV001, ASN-002, Ruxotemitide, CX-4945, PTX-022, GZ17-6.02, L19IL2/L19TNF, INCB099318, and others.
- Several basal cell carcinoma therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major basal cell carcinoma market share @ Basal Cell Carcinoma Market Report
Basal Cell Carcinoma Overview
Basal cell carcinoma (BCC) is the most common type of skin cancer and the most common type of cancer overall. Basal cell carcinoma develops on sun-damaged skin and rarely on mucous membranes, palms, and soles. Basal cell carcinoma is typically a slow-growing tumor with few metastases. Although basal cell carcinoma is rarely fatal, it can be extremely destructive and disfigure local tissues if treatment is insufficient or delayed. There are over 26 different subtypes of BCC, but the most common and distinct clinicopathologic types are: nodular, micronodular, superficial, morpheaform, infiltrative, and fibro epithelial.
A skin biopsy is required for clinical confirmation of basal cell carcinoma. A shave, punch, or excisional biopsy are all options, with care taken to include some dermis in the specimen to differentiate between superficial and other invasive histologic subtypes of basal cell carcinoma. Dermoscopy can help experienced clinicians diagnose non-pigmented and pigmented Basal cell carcinomas. Adnexal tumors with follicular, sweat gland, or sebaceous differentiation, as well as certain types of squamous cell carcinoma, are in the differential basal cell carcinoma diagnosis.
Basal Cell Carcinoma Epidemiology Segmentation
According to the American Cancer Society (ACS) (2022), reports skin cancer as being the most common cancer in the United States, with basal cell carcinoma (BCC) constituting the majority of cases. The ACS cites an estimate that about 5.4 million basal and squamous cell skin cancers are diagnosed yearly in about 3.3 million persons in the US, with about 80% of those being BCCs.
The basal cell carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalent cases of Skin Caner
- Total Non-melanoma Prevalent cases
- Subtpye-Specific Prevalent cases of Basal Cell Carcinoma
- Basal Cell Carcinoma Prevalent Cases
- Stage-Specific Prevalent cases of Basal Cell Carcinoma
Download the report to understand which factors are driving basal cell carcinoma epidemiology trends @ Basal Cell Carcinoma Epidemiological Insights
Basal Cell Carcinoma Treatment Market
The choice of therapy is determined by the patient’s age and gender, location, size, and type of lesion. There is no single basal cell carcinoma treatment method that is best for all lesions or all patients. All patients with suspected basal cell carcinoma should have a biopsy to confirm the basal cell carcinoma diagnosis and determine the histologic subtype. Basal cell carcinoma is usually treated surgically, but some types of basal cell carcinoma can be treated medically or with radiation therapy. Mohs micrographic surgery (MMS), standard surgical excision, EDC, radiation, photodynamic therapy, cryosurgery, topical therapies, and systemic medications such as Vismodegib are among the various types of therapy.
Mohs micrographic surgery (MMS) has the highest long-term cure rate for Basal cell carcinoma of any treatment modality. Because of its high cure rate and tissue-sparing benefit, it is the gold standard for treating high-risk BCCs and recurrent BCCs. When compared to standard vertical sectioning, which only examines less than 1% of the outer peripheral and deep margins, the high cure rate is attributed to the examination of 100% of all tissue margins.
To know more about basal cell carcinoma treatment, visit @ Basal Cell Carcinoma Treatment Drugs
Key Basal Cell Carcinoma Therapies and Companies
- Remetinostat: Medivir
- STP705: Sirnaomics
- AIV001: AiViva BioPharma, Inc.
- ASN-002: Ascend Biopharmaceuticals Ltd
- Ruxotemitide: Lytix Biopharma
- CX-4945: Senhwa Biosciences, Inc.
- PTX-022: Palvella Therapeutics, Inc.
- GZ17-6.02: Genzada Pharmaceuticals USA, Inc.
- L19IL2/L19TNF: Philogen S.p.A.
- INCB099318: Incyte Corporation
Learn more about the FDA-approved drugs for basal cell carcinoma @ Drugs for Basal Cell Carcinoma Treatment
Basal Cell Carcinoma Market Dynamics
The dynamics of the basal cell carcinoma market is anticipated to change in the coming years owing to the advancement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and advancements in research and development undertaking. Basal cell carcinoma (BCC) is the most common type of skin cancer and the most common type of cancer overall. The choice of therapy is determined by the patient’s age and gender, location, size, and type of lesion. There is no single treatment method that is best for all lesions or all patients. Basal cell carcinoma is usually treated surgically, but some types of BCC can be treated medically or with radiation therapy.
Moreover, several key players are involved in developing therapies for basal cell carcinoma treatment. Many potential therapies are being investigated to treat basal cell carcinoma, and it is safe to predict that the treatment space will significantly impact the basal cell carcinoma market during the forecast period. The anticipated introduction of new therapies with improved efficacy, increased awareness initiatives, and further improvement in the diagnosis rate are expected to drive the growth of the 7MM basal cell carcinoma market.
However, the basal cell carcinoma market growth may be hampered by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the basal cell carcinoma market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Basal Cell Carcinoma Companies | Medivir, Sirnaomics, AiViva BioPharma, Inc., Ascend Biopharmaceuticals Ltd, Lytix Biopharma, Senhwa Biosciences, Inc., Palvella Therapeutics, Inc., Genzada Pharmaceuticals USA, Inc., Philogen S.p.A., Incyte Corporation, and others |
| Key Basal Cell Carcinoma Therapies | Remetinostat, STP705, AIV001, ASN-002, Ruxotemitide, CX-4945, PTX-022, GZ17-6.02, L19IL2/L19TNF, INCB099318, and others |
Scope of the Basal Cell Carcinoma Market Report
- Therapeutic Assessment: Basal Cell Carcinoma current marketed and emerging therapies
- Basal Cell Carcinoma Market Dynamics: Attribute Analysis of Emerging Basal Cell Carcinoma drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Basal Cell Carcinoma Market Access and Reimbursement
Discover more about basal cell carcinoma drugs in development @ Basal Cell Carcinoma Clinical Trials
Table of Contents
| 1. | Basal Cell Carcinoma Market Key Insights |
| 2. | Basal Cell Carcinoma Market Report Introduction |
| 3. | Basal Cell Carcinoma Market Overview at a Glance |
| 4. | Basal Cell Carcinoma Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Basal Cell Carcinoma Treatment and Management |
| 7. | Basal Cell Carcinoma Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Basal Cell Carcinoma Marketed Drugs |
| 10. | Basal Cell Carcinoma Emerging Drugs |
| 11. | Seven Major Basal Cell Carcinoma Market Analysis |
| 12. | Basal Cell Carcinoma Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Basal Cell Carcinoma Market Drivers |
| 16. | Basal Cell Carcinoma Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Related Reports
Basal Cell Carcinoma Epidemiology Forecast
Basal Cell Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted basal cell carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Basal Cell Carcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key basal cell carcinoma companies, including PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, among others.
Nonmelanoma Skin Cancer Pipeline
Nonmelanoma Skin Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonmelanoma skin cancer companies, including Sirnaomics, AiViva BioPharma, Exicure, Sanofi, Genentech, among others.
Nonmelanoma Skin Cancer Epidemiology Forecast
Nonmelanoma Skin Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted nonmelanoma skin cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nonmelanoma Skin Cancer Market
Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nonmelanoma skin cancer companies, including Sirnaomics, AiViva BioPharma, Exicure, Sanofi, Genentech, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Basal Cell Carcinoma Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
